Atlas Trials

Relative Bioavailability Study of CX2101A for the Treatment of COVID-19

Clinical trial NCT06864182 · COMPLETED

Trial details

NCT number
NCT06864182
Sponsor
Heronova Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
COVID-19Coronavirus Infection
Start date
2024-03-21
Primary completion
2024-05-25
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.